Reckitt buys Paras for $726 million

As the year draws to a close, private-equity firm Actis orchestrates the sale of its portfolio company Paras Pharmaceuticals in India to Reckitt Benckiser for $726 million.
December 13, 2010

Private equity deal goes sour in India

It looked like a done deal, but ActisÆ (erstwhile the UK's CDC) attempt to buy into one of IndiaÆs only remaining large confectionery players is called off at the final stage.
March 08, 2006

Actis bets on wolfberries

International private equity comes to the world of wolfberries in a fruitful deal.
September 21, 2004